表紙
市場調查報告書

亞太地區的血糖儀市場(2012年∼2024年)

Asia-pacific Blood Glucose Monitoring Market - Growth, Trends, and Forecast (2012 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 808260
出版日期 內容資訊 英文 85 Pages
商品交期: 2-3個工作天內
價格
Back to Top
亞太地區的血糖儀市場(2012年∼2024年) Asia-pacific Blood Glucose Monitoring Market - Growth, Trends, and Forecast (2012 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 85 Pages
簡介

亞太地區的血糖儀市場預測從2019年到2024年間,將以8.83%的年複合成長率發展,成長到2019年的20億美元。

本報告提供亞太地區的血糖儀市場調查,市場概要,各類別、各國市場規模的變化與預測,市場成長要素及阻礙因素分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 市場分析:血糖自我測量儀
    • 各零件
      • 血糖儀
      • 測試紙
      • 採血針
    • 各終端用戶
      • 醫院
      • 個人
  • 市場分析:持續血糖儀
    • 各零件
  • 各地區
    • 亞太地區
      • 日本
      • 韓國
      • 中國
      • 印度
      • 澳洲
      • 越南
      • 馬來西亞
      • 印尼
      • 菲律賓
      • 泰國
      • 其他

第6章 市場指標

  • 第一型糖尿病人口(實在數值、預測值)
  • 第二型糖尿病人口(實在數值、預測值)

第7章 競爭情形

  • 企業簡介
    • Abbott Diabetes Care
    • Roche
    • Johnson & Johnson
    • Dexcom
    • Medtronic
    • Arkray
    • Ascensia Diabetes Care
    • Agamatrix Inc.
    • Bionime Corporation
    • Acon
    • Medisana
    • Trivida
    • Rossmax
  • 企業佔有率分析
    • Roche
    • Johnson & Johnson
    • Abbott Diabetes Care
    • Dexcom
    • Medtronics
    • 其他

第8章 市場機會與未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 49054

Market Overview

The Asia-Pacific blood glucose monitoring market is expected to register a CAGR of 8.83% during the forecast period (2019 - 2024), and the market is estimated to reach USD 2 billion by 2019.

Asia-Pacific has countries with the highest diabetic populations, such as China and India, with an average prevalence rate of more than 8%.

Blood glucose monitoring devices are used for effective diabetes diagnosis and treatment. A rise in the diabetic population drives the market by increasing the use of blood glucose monitoring devices.

Obesity is also considered one of the major factors contributing to the disease condition, mainly type 2 diabetes.

Also, other factors such as technological innovations and advances provide convenience in measuring blood glucose levels. One such advancement in monitoring blood glucose levels was established by continuous glucose monitoring devices.

These devices help in early detection of hypo- and hyperglycemic conditions, which tend to drive the market for glucose monitoring market.

Scope of the Report

The two main types of blood glucose monitoring devices are included in this study. These devices are further categorized into the self-monitoring blood glucose devices [(SMBG) segmented into glucometer devices, test strips, and lancets (which are also studied by their usage in hospital and home use, individually)] and continuous glucose monitoring [(CGM) devices segmented into sensors and receivers].

Key Market Trends - Self-monitoring Blood Glucose Devices Have High Demand

Although CGM is an advanced method for people living with diabetes to check glucose readings in real-time, SMBGs are the most preferred devices by patients in Asia-Pacific, due to their economic affordability and lesser sophistications in usage, when compared to CGM.

The SMBG segment occupies more than 93% of the market share in the Asia-Pacific blood glucose monitoring market. The further segmented market of SMBG uncovers the following understanding, that disposable consumables (test strips and lancets) occupy the largest market share compared to glucometer devices.

China and India rank high in terms of diabetic populations around the globe, and the market for diabetes is expected to increase at a high rate in these two countries during the forecast period.

Although CGM provides real-time data of blood glucose levels for patients, its adaptability is very low in Asia-Pacific markets. The cost factor is a major concern for the low growth of CGM in the Asia-Pacific market.

China Leading the Asia-Pacific Market

China is facing the largest diabetes epidemic in the world, with around 11% of its population suffering from metabolic illness, while nearly 36% are pre-diabetic.

In 2018, China held the largest share in the Asia-Pacific blood glucose monitoring market due to the large patient pool and wide acceptance of advanced technologies.

Competitive Landscape

The Asia-Pacific blood glucose monitoring market is highly fragmented with few major manufacturers having a presence in major countries of the Asia-Pacific market, while the remaining manufacturers stayed confined to the other local or region-specific markets.

Mergers and acquisitions between players in the recent past helped companies strengthen their market presence. For example, Ascensia Diabetes Care (the Swiss tech company, originally formed a few years ago from a merger of Bayer Health's diabetes division and Panasonic Healthcare) is officially moving into the CGM space via a partnership with Huzhou, China-based Zhejiang POCTech.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Self-monitoring Blood Glucose Devices
    • 5.1.1 By Component (Market Size, Value and Volume)
      • 5.1.1.1 Glucometer Devices
      • 5.1.1.2 Test Strips
      • 5.1.1.3 Lancets
    • 5.1.2 By End User
      • 5.1.2.1 Hospitals (Market Size, Value and Volume)
      • 5.1.2.1.1 Glucometer Devices
      • 5.1.2.1.2 Test Strips
      • 5.1.2.1.3 Lancets
      • 5.1.2.2 Personal (Market Size, Value and Volume)
      • 5.1.2.2.1 Glucometer Devices
      • 5.1.2.2.2 Test Strips
      • 5.1.2.2.3 Lancets
  • 5.2 Continuous Blood Glucose Monitoring Devices
    • 5.2.1 By Component (Market Size, Value and Volume)
      • 5.2.1.1 Sensors
      • 5.2.1.2 Receivers
  • 5.3 Geography
    • 5.3.1 Asia-Pacific
      • 5.3.1.1 Japan (Market Size, Value and Volume)
      • 5.3.1.1.1 Self-monitoring Blood Glucose Devices
      • 5.3.1.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.3.1.1.1.2 By End User (Hospital and Home)
      • 5.3.1.1.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.3.1.1.2 Continuous Glucose Monitoring Devices
      • 5.3.1.1.2.1 By Component (Sensors and Receivers)
      • 5.3.1.1.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
      • 5.3.1.2 South Korea (Market Size, Value and Volume)
      • 5.3.1.2.1 Self-monitoring Blood Glucose Devices
      • 5.3.1.2.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.3.1.2.1.2 By End User (Hospital and Home)
      • 5.3.1.2.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.3.1.2.2 Continuous Glucose Monitoring Devices
      • 5.3.1.2.2.1 By Component (Sensors and Receivers)
      • 5.3.1.2.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
      • 5.3.1.3 China (Market Size, Value and Volume)
      • 5.3.1.3.1 Self-monitoring Blood Glucose Devices
      • 5.3.1.3.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.3.1.3.1.2 By End User (Hospital and Home)
      • 5.3.1.3.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.3.1.3.2 Continuous Glucose Monitoring Devices
      • 5.3.1.3.2.1 By Component (Sensors and Receivers)
      • 5.3.1.3.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
      • 5.3.1.4 India (Market Size, Value and Volume)
      • 5.3.1.4.1 Self-monitoring Blood Glucose Devices
      • 5.3.1.4.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.3.1.4.1.2 By End User (Hospital and Home)
      • 5.3.1.4.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.3.1.4.2 Continuous Glucose Monitoring Devices
      • 5.3.1.4.2.1 By Component (Sensors and Receivers)
      • 5.3.1.4.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
      • 5.3.1.5 Australia (Market Size, Value and Volume)
      • 5.3.1.5.1 Self-monitoring Blood Glucose Devices
      • 5.3.1.5.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.3.1.5.1.2 By End User (Hospital and Home)
      • 5.3.1.5.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.3.1.5.2 Continuous Glucose Monitoring Devices
      • 5.3.1.5.2.1 By Component (Sensors and Receivers)
      • 5.3.1.5.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
      • 5.3.1.6 Vietnam (Market Size, Value and Volume)
      • 5.3.1.6.1 Self-monitoring Blood Glucose Devices
      • 5.3.1.6.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.3.1.6.1.2 By End User (Hospital and Home)
      • 5.3.1.6.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.3.1.6.2 Continuous Glucose Monitoring Devices
      • 5.3.1.6.2.1 By Component (Sensors and Receivers)
      • 5.3.1.6.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
      • 5.3.1.7 Malaysia (Market Size, Value and Volume)
      • 5.3.1.7.1 Self-monitoring Blood Glucose Devices
      • 5.3.1.7.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.3.1.7.1.2 By End User (Hospital and Home)
      • 5.3.1.7.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.3.1.7.2 Continuous Glucose Monitoring Devices
      • 5.3.1.7.2.1 By Component (Sensors and Receivers)
      • 5.3.1.7.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
      • 5.3.1.8 Indonesia (Market Size, Value and Volume)
      • 5.3.1.8.1 Self-monitoring Blood Glucose Devices
      • 5.3.1.8.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.3.1.8.1.2 By End User (Hospital and Home)
      • 5.3.1.8.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.3.1.8.2 Continuous Glucose Monitoring Devices
      • 5.3.1.8.2.1 By Component (Sensors and Receivers)
      • 5.3.1.8.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
      • 5.3.1.9 Philippines (Market Size, Value and Volume)
      • 5.3.1.9.1 Self-monitoring Blood Glucose Devices
      • 5.3.1.9.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.3.1.9.1.2 By End User (Hospital and Home)
      • 5.3.1.9.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.3.1.9.2 Continuous Glucose Monitoring Devices
      • 5.3.1.9.2.1 By Component (Sensors and Receivers)
      • 5.3.1.9.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
      • 5.3.1.10 Thailand (Market Size, Value and Volume)
      • 5.3.1.10.1 Self-monitoring Blood Glucose Devices
      • 5.3.1.10.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.3.1.10.1.2 By End User (Hospital and Home)
      • 5.3.1.10.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.3.1.10.2 Continuous Glucose Monitoring Devices
      • 5.3.1.10.2.1 By Component (Sensors and Receivers)
      • 5.3.1.10.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
      • 5.3.1.11 Rest of Asia-Pacific (Market Size, Value and Volume)
      • 5.3.1.11.1 Self-monitoring Blood Glucose Devices
      • 5.3.1.11.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.3.1.11.1.2 By End User (Hospital and Home)
      • 5.3.1.11.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.3.1.11.2 Continuous Glucose Monitoring Devices
      • 5.3.1.11.2.1 By Component (Sensors and Receivers)
      • 5.3.1.11.2.2 By Company (Dexcom, Abbott, Medtronics and Others)

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population (2012-2024)
  • 6.2 Type-2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Abbott Diabetes Care
    • 7.1.2 Roche
    • 7.1.3 Johnson & Johnson
    • 7.1.4 Dexcom
    • 7.1.5 Medtronic
    • 7.1.6 Arkray
    • 7.1.7 Ascensia Diabetes Care
    • 7.1.8 Agamatrix Inc.
    • 7.1.9 Bionime Corporation
    • 7.1.10 Acon
    • 7.1.11 Medisana
    • 7.1.12 Trivida
    • 7.1.13 Rossmax
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Roche
    • 7.2.2 Johnson & Johnson
    • 7.2.3 Abbott Diabetes Care
    • 7.2.4 Dexcom
    • 7.2.5 Medtronics
    • 7.2.6 Others

8 MARKET OPPORTUNITES AND FUTURE TRENDS

Back to Top